Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were -0.79% and -0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, -0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (-11.9% vs. -4.8%; P < .0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dom.14085 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
LONP1 Variants Are Associated With Clinically Diverse Phenotypes.
Clin Genet
September 2025
Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
LONP1 encodes a mitochondrial protease essential for protein quality control and metabolism. Variants in LONP1 are associated with a diverse and expanding spectrum of disorders, including Cerebral, Ocular, Dental, Auricular, and Skeletal anomalies syndrome (CODAS), congenital diaphragmatic hernia (CDH), and neurodevelopmental disorders (NDD), with some individuals exhibiting features of mitochondrial encephalopathy. We report 16 novel LONP1 variants identified in 16 individuals (11 with NDD, 5 with CDH), further expanding the clinical spectrum.
View Article and Find Full Text PDFConnecting the Dots: Hepatic Steatosis as a Central Player in the Choreography of the Liver-Cardiovascular-Kidney-Metabolic Syndrome.
Heart Lung Circ
September 2025
Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, WA, Australia; Medical School, The University of Western Australia, Perth, WA, Australia; Curtin Medical School, Curtin University, Bentley, WA, Australia. Electronic address:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, with a reach extending beyond the liver to include other metabolic syndrome-related disorders. Cardiovascular disease and type 2 diabetes mellitus are recognised non-communicable disorders and often downstream complications of MASLD and share similar risk factors. However, MASLD has not been afforded parity alongside other cardiometabolic non-communicable disorders, including the cardiovascular-kidney-metabolic (CKM) syndrome.
View Article and Find Full Text PDFMetabolic dysfunction-associated steatotic liver disease and dietary intake characteristics in children and adolescents: A cross-sectional study.
Rev Gastroenterol Mex (Engl Ed)
September 2025
Facultad de Nutrición, Universidad Federal de Bahía (UFBA), Salvador, Bahía, Brazil.
Introduction And Aims: Metabolic dysfunction-associated steatotic disease (MASLD) is the most common cause of chronic liver disease in children and adolescents. The development of MASLD is associated with dietary habits, and dietary intake characteristics are a relevant risk factor. The aim of the present study was to analyze dietary intake characteristics in children and adolescents and study how diet varies in subjects with and without MASLD.
View Article and Find Full Text PDFEosinophilic granulomatosis with polyangiitis complicated with bullous pemphigoid.
BMJ Case Rep
September 2025
Division of Neurology, Department of Internal Medicine, Nihon University School of Medicine, Itabashi, Tokyo, Japan.
Eosinophilic granulomatosis with polyangiitis (EGPA) and bullous pemphigoid (BP) are both autoimmune diseases characterised by eosinophilic involvement. Coexistence of the two diseases is rare, and confirmatory immunological analyses for BP are lacking in such cases. Here, we report a male in his 80s diagnosed with EGPA 5 years previously who developed numbness and tense blisters but showed no peripheral eosinophilia.
View Article and Find Full Text PDFSeizures and hypoparathyroidism post-thyroidectomy: Fahr's syndrome.
BMJ Case Rep
September 2025
Gandhi Medical College and Hospital, Secunderabad, Telangana, India
Fahr's syndrome is a rare neurological condition marked by unusual calcifications in the basal ganglia and other brain regions, often resulting from metabolic disorders, such as hypoparathyroidism. Secondary hypoparathyroidism, a frequent complication of total thyroidectomy, can lead to Fahr's syndrome, manifesting as movement disorders, seizures, psychiatric symptoms and indications of calcium deficiency. This case report discusses a woman in her mid-30s who developed Fahr's syndrome due to secondary hypoparathyroidism after total thyroidectomy.
View Article and Find Full Text PDF